The Leeds-based firm said its Pinnacle product is the system used by healthcare professionals throughout England, delivering Covid-19 vaccinations to capture and share essential immunisation information.

Pinnacle is being used by healthcare professionals in GP-led primary care, community pharmacy and mass vaccination centres, linking directly with the National Immunisation Management Service for vital data exchange and sharing Covid-19 vaccination data back into the GP record.

The system has also underpinned the NHS daily reporting on vaccination delivery.

Announcing results for the year to December 31, Emis reported a resilient financial performance with recurring revenue up 4 per cent to £130m and an increased final dividend for the tenth consecutive year.

The firm said it is well positioned to meet evolving requirements of healthcare sector today and in the future.

The company has supported large-scale epidemiological Covid-19 research with NHS England, Oxford University and the London School of Tropical Hygiene & Medicine.

It is also working alongside Oxford University to undertake a major clinical research project in the treatment of Covid-19.

The firm said it expects to return to growth in 2021, with new product developments leading to opportunities for higher growth levels in 2022 and beyond.

Andy Thorburn, chief executive of Emis Group, said: “2020 has been another year of positive progress for Emis Group, during which healthcare has been at the centre of the global agenda.

“The front line response to the pandemic has been outstanding and I am proud of all my colleagues who have stepped up and helped our NHS heroes in every possible way, from supporting the clinicians delivering patient care on the front line to playing a vital role in England’s vaccination programme.

“While Covid-19 presented unprecedented challenges to the sector, it has also been a catalyst for change, leading to a more rapid adoption of digital healthcare that is here to stay. We believe that Emis Group is well positioned to respond to the challenges our customers face, with a combination of our innovative technology, leading market shares and strong recurring revenues that enable us to invest with confidence.”